EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study

Sandro Saviano, Pia Easter Leon, Alessandro Mangogna, Daniele Tognetto

Digital Journal of Ophthalmology · 2016

DOI: 10.5693/djo.01.2014.01.004 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Digital Journal of Ophthalmology, 2016. Verfasst von Sandro Saviano und 3 weiteren Autor:innen. Beteiligte Einrichtung: University Eye Clinic of Trieste. Ospedale Maggiore, Trieste, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PurposeTo assess the efficacy and safety of combined intravitreal bevacizumab and low-fluency-rate photodynamic therapy (PDT) in the treatment of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) and to compare it with intravitreal bevacizumab monotherapy. MethodsA total of 62 eyes of 62 patients with angiographic evidence of CNV were divided into 2 groups: the eyes of one group were treated with a combined therapy of 1 intravitreal bevacizumab injection (1.25 mg) and PDT within 7 days; the eyes of the other group received intravitreal bevacizumab monotherapy. Clinical evidence of complications, best-corrected visual acuity (BVCA) and fluorescein leakage were evaluated. Best-corrected visual acuity and optical coherence tomography (OCT) were tested monthly and followed for 12 months. ResultsIn the combined group the mean BCVA increased from 0.61 logMAR before the treatment to 0.54 logMAR at 12 months’ follow-up. In the monotherapy group the mean BCVA increased from 0.65 logMAR to 0.60 logMAR at 12 months’ follow-up. There was no significant difference in visual acuity outcomes between groups (P > 0.05). In the combined group the mean number of treatments was 1.19 per patient; in the monotherapy group, 5.31 per patient (P < 0.01). ConclusionsCombined therapy appears to be an effective option for CNV associated with AMD treatment allowing a significant reduction of intravitreal injections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAngiogenesis InhibitorsBevacizumabChoroidal NeovascularizationDose-Response Relationship, DrugDrug Therapy, CombinationFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMacular DegenerationMalePhotochemotherapyPhotosensitizing AgentsPorphyrinsRetrospective StudiesTime FactorsTomography, Optical Coherence

Substanzen

Angiogenesis InhibitorsPhotosensitizing AgentsPorphyrinsVerteporfinBevacizumab

Autor:innen und Institutionen

  • University Eye Clinic of Trieste. Ospedale Maggiore, Trieste, Italy.

Zitieren

APA

Saviano, S., Leon, P. E., Mangogna, A., & Tognetto, D. (2016). Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Digital Journal of Ophthalmology. https://doi.org/10.5693/djo.01.2014.01.004

Vancouver

Saviano S, Leon PE, Mangogna A, Tognetto D. Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study. Digital Journal of Ophthalmology. 2016. doi:10.5693/djo.01.2014.01.004

BibTeX
@article{Saviano2016,
  author = {Saviano, Sandro and Leon, Pia Easter and Mangogna, Alessandro and Tognetto, Daniele},
  title = {Combined therapy (intravitreal bevacizumab plus verteporfin photodynamic therapy) versus intravitreal bevacizumab monotherapy for choroidal neovascularization due to age-related macular degeneration: a 1-year follow-up study},
  journal = {Digital Journal of Ophthalmology},
  year = {2016},
  doi = {10.5693/djo.01.2014.01.004}
}
Kostenlos starten →